Bayer Ag (adr) Stock News

German diversified group Bayer has seen a "very successful start to the year", driven by a favourable environment in agricultural markets, it said on Monday.

Norway's $1.3 trillion wealth fund will cast a vote in support next week of top management at German drug and farm products maker Bayer AG, but will vote against the remuneration package of CEO Werner

Two health care companies most investors might not be familiar with were among the four biggest stock market gainers in the first quarter, according to an analysis by Evaluate.

Bayer's technical picture improved in the last few months, and the company also reported solid fiscal 2021 results.

The DAX index made a spectacular recovery in the first quarter in sync with other top indices. It rose by more than 16% from its lowest level this year even as risks to the German economy remained.

German drugmaker Bayer said it would invest around 2 billion euros ($2.23 billion) at pharmaceutical manufacturing sites over the next three years, mainly to bolster production of biotechnology drugs

Bayer shareholder Union Investment on Monday came out in support of the drugmaker's chief executive serving out his full term after the CEO came under renewed pressure over the company's performance.

Experts say CRISPR-based treatments could soon constitute a massive market — and the prospects are grabbing Big Pharma's attention. Investor's Business Daily has been helping people invest smarter r

Bayer AG reached an $80 million settlement with Ohio to resolve environmental damage allegedly caused by polychlorinated biphenyls, or PCBs, made by the company's Monsanto business, the state attorney

SHANGHAI, CHINA, Mar 17, 2022 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. The New Drug Application (NDA) of dorzagliatin for the treatment of Type 2 Diabetes was submitted to, and accepted by, the China National Medical Products Administration (the "NMPA"). The Company has also been actively advancing the full-life-cycle management plans of drugs. Total expenditures incurred by the Company in 2021 was approximately RMB327.2 million, of which approximately RMB186.8 million was research and development expenses. As of December 31, 2021, the Company''s cash position was approximately RMB675.2 million. Hua Medicine has consistently focused on unmet clinical needs. After 10 years of breakthrough exploration, from the scientific theory of glucose homeostasis regulation to an innovative drug with a new and novel mechanism, the Company has successfully developed dorzagliatin, a first-in-class innovative glucokinase activator for Type 2 Diabetes.

San Francisco-headquartered company has secured over $123.5m in funding to date

Rabobank: Food, Energy, Goods And Finance Are Being Used As A Weapon By Michael Every of Rabobank “Risk” is on. I don’t mean market risk: not when Western stocks are slumping after yet another head-fake rally, the Nasdaq now in a bear market again; not when Chinese stocks are experiencing a 2008-style collapse – and who knew geopolitics and ideology still mattered in a highly geopolitical, openly Leninist political-economy?; not when oil prices are down 35% from their recent high; and not when US Treasury yields are surging, and the 5s-10s curve is close to inverting even before the Fed meeting this week. No, that is all very much risk off, even as some will cling to the hope that China slashing banks’ reserve requirement ratios and rates, even as the Fed hikes, and despite its surprise failure to cut 10bp to 2.75% today as expected , is good news. What I mean that the boardgame “Risk” is on , which I used as a visual analogy of where geoeconomics would end up once neoliberal free trade failed in 2017’s ‘ The Great Game of Global Trade ’.

Pfizer (PFE) and Bayer (BAYZF) (BAYRY) announced on Monday that they would scale back certain business operations in Russia as western companies continue to leave the country in the wake…

FRANKFURT (Reuters) – Germany’s Bayer on Monday stopped all spending in Russia and Belarus not related to essential products in health and agriculture, citing Russia’s “brutal aggression” against Ukraine.

Germany's Bayer on Monday stopped all spending in Russia and Belarus not related to essential products in health and agriculture, citing Russia's "brutal aggression" against Ukraine.